Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 7/20 | 0.48 |
| ▸ | ACACB | O00763 | 13/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604785 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL29604275 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL19894586 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL16695474 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL19894457 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL19894459 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL29604649 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL16695549 | 1.00 | UGCG (0.48) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL18094879 | 0.91 | UGCG (0.49) | UGCGACACBHTR1APTGS1OPRM1 | |
| SCHEMBL16695111 | 0.91 | UGCG (0.49) | UGCGACACBHTR1APTGS1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | claimed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | claimed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | claimed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2019-09-12 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3063141-B1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARM INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | UGCG 2/4885ACACB 71/4885HTR1A 3038/4885 |
| US-20190276398-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | UGCG 2/4885ACACB 71/4885HTR1A 3038/4885 |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | UGCG 2/4885ACACB 92/4885HTR1A 2749/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | UGCG 2/4885ACACB 92/4885HTR1A 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.